Table 1 Baseline clinical variables, medical history, echocardiographic measurements, medical therapy and laboratory parameters
From: Effect of single ventricular premature contractions on response to cardiac resynchronization therapy
Baseline clinical variables | All patients (n = 67) | Low PVCs (n = 34) | High PVCs (n = 33) | P-value |
|---|---|---|---|---|
No. of single PVCs (no., IQR) | 11,401 (725/48 K) | |||
Age (years, mean ± SD) | 66.2 ± 10.2 | 64.5 ± 11.3 | 68.5 ± 8.4 | 0.16 |
Gender (female, n, %) | 14 (21%) | 10 (29%) | 4 (12%) | 0.13 |
Ischemic etiology (n, %) | 35 (52%) | 16 (47%) | 19 (58%) | 0.47 |
NYHA (stadium, mean ± SD) | 3.2 ± 2.0 | 3.1 ± 2.0 | 3.3 ± 2.0 | 0.21 |
QRS (ms, mean ± SD) | 162 ± 24 | 168 ± 25 | 157 ± 22 | 0.10 |
typical LBBB morphology (n, %) | 49 (73%) | 26 (77%) | 23 (70%) | 0.59 |
not typical LBBB (n, %) | 18 (27%) | 8 (24%) | 10 (30%) | 0.59 |
6MWT (m, mean ± SD) | 295.9 ± 125.7 | 318.0 ± 119.6 | 276.3 ± 129.9 | 0.23 |
RR systolic (mmHg, mean ± SD) | 121.9 ± 18.3 | 121.4 ± 18.3 | 122.5 ± 18.1 | 0.81 |
RR diastolic (mmHg, mean ± SD) | 74.1 ± 10.2 | 73.3 ± 9.6 | 74.9 ± 10.9 | 0.52 |
Heart rate (min−1, mean ± SD) | 73.4 ± 13.4 | 72.3 ± 12.0 | 74.6 ± 14.8 | 0.52 |
Sinus rhythm (n, %) | 55 (82%) | 29 (86%) | 26 (79%) | 0.54 |
Medical history | ||||
Hypertension (n, %) | 46 (69%) | 23 (68%) | 23 (70%) | 1.00 |
Type 2 diabetes mellitus (n, %) | 22 (33%) | 12 (35%) | 10 (30%) | 0.78 |
Prior myocardial infarction (n, %) | 17 (25%) | 10 (29%) | 7 (21%) | 0.58 |
Prior PCI (n, %) | 17 (25%) | 9 (27%) | 8 (24%) | 1.00 |
Prior CABG (n, %) | 10 (15%) | 3 (9%) | 7 (21%) | 0.19 |
Prior COPD (n, %) | 4 (6%) | 1 (3%) | 3 (9%) | 0.36 |
Echocardiographic parameters | ||||
LVEF (%, mean ± SD) | 29.0 ± 6.0 | 30.4 ± 6.7 | 27.7 ± 5.1 | 0.14 |
LVESV (ml, mean ± SD) | 183.8 ± 68.1 | 170.7 ± 63.0 | 196.8 ± 72.1 | 0.24 |
LAV (ml, mean ± SD) | 87.6 ± 26.8 | 94.1 ± 25.6 | 81.9 ± 27.3 | 0.18 |
Baseline medical therapy | ||||
Beta blocker (n, %) | 61 (91%) | 32 (94%) | 29 (88%) | 0.43 |
ACE inhibitor or ARB (n, %) | 63 (94%) | 32 (94%) | 31 (94%) | 1.00 |
MRA (n, %) | 44 (66%) | 22 (65%) | 22 (67%) | 1.00 |
Diuretics (n, %) | 55 (82%) | 24 (88%) | 31 (94%) | 0.06 |
Digoxin (n, %) | 15 (22%) | 8 (24%) | 7 (21%) | 1.00 |
Amiodarone (n, %) | 17 (25%) | 12 (35%) | 5 (15%) | 0.09 |
Oral anticoagulant therapy (n, %) | 21 (31%) | 8 (24%) | 13 (39%) | 0.19 |
Baseline laboratory parameters | ||||
Sodium (mmol/L, mean ± SD) | 138.6 ± 2.7 | 139.0 ± 2.5 | 138.1 ± 2.8 | 0.18 |
Potassium (mmol/L, mean ± SD) | 4.6 ± 0.5 | 4.6 ± 0.6 | 4.5 ± 0.4 | 0.33 |
Creatinine (μmol/L, mean ± SD) | 110.1 ± 44.1 | 120.7 ± 52.2 | 99.2 ± 30.9 | 0.07 |
BUN (mmol/L, mean ± SD) | 9.8 ± 5.3 | 9.7 ± 4.0 | 9.8 ± 6.4 | 0.23 |